CL2017000191A1 - Método - Google Patents

Método

Info

Publication number
CL2017000191A1
CL2017000191A1 CL2017000191A CL2017000191A CL2017000191A1 CL 2017000191 A1 CL2017000191 A1 CL 2017000191A1 CL 2017000191 A CL2017000191 A CL 2017000191A CL 2017000191 A CL2017000191 A CL 2017000191A CL 2017000191 A1 CL2017000191 A1 CL 2017000191A1
Authority
CL
Chile
Prior art keywords
subject
agent
administrating
union
therapy
Prior art date
Application number
CL2017000191A
Other languages
English (en)
Inventor
Christian Kjellman
Sofia Jarnum
Lena Winstedt
Original Assignee
Hansa Medical Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hansa Medical Ab filed Critical Hansa Medical Ab
Publication of CL2017000191A1 publication Critical patent/CL2017000191A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4873—Cysteine endopeptidases (3.4.22), e.g. stem bromelain, papain, ficin, cathepsin H
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)

Abstract

<p>LA INVENCIÓN SE REFIERE A UN MÉTODO PARA MEJORAR EL BENEFICIO DE UNA TERAPIA O UN AGENTE TERAPÉUTICO PARA UN SUJETO. EL MÉTODO COMPRENDE (A) ADMINISTRAR AL SUJETO UN AGENTE QUE REDUCE LIA UNIÓN AL RECEPTOR Fc DE MOLÉCULAS DE IgG EN SUERO EN EL SUJETO; Y ADMINISTRAR POSTERIORMENTE DICHA TERAPIA O DICHO AGENTE TERAPÉUTICO AL SUJETO. LA INVENCIÓN SE REFIERE TAMBIÉN A UN MÉTODO PARA REDUCIR EL EFECTO DE AUTOANTICUERPOS PATÓGENOS EN UN SUJETO, COMPRENDIENDO EL MÉTODO (A) ADMINISTRAR AL SUJETO UN AGENTE QUE REDUCE LA UNIÓN AL RECEPTOR DE Fc DE MOLÉCULAS DE IgG EN SUERO EN EL SUJETO Y OPCIONALMENTE (B) SOMETER SUBSECUENTEMENTE AL SUJETO A UN TRATAMIENTO QUE ELIMINA AUTOANTICUERPOS ENDÓGENOS. LA INVENCIÓN SE REFIERE TAMBIÉN A UN KIT PARA LLEVAR A CABO UN MÉTODO DE LA INVENCIÓN.</p>
CL2017000191A 2014-07-25 2017-01-25 Método CL2017000191A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1413240.1A GB201413240D0 (en) 2014-07-25 2014-07-25 Method

Publications (1)

Publication Number Publication Date
CL2017000191A1 true CL2017000191A1 (es) 2017-08-25

Family

ID=51587261

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000191A CL2017000191A1 (es) 2014-07-25 2017-01-25 Método

Country Status (26)

Country Link
US (3) US10973889B2 (es)
EP (2) EP3171891B1 (es)
JP (1) JP6708641B2 (es)
KR (2) KR20230119267A (es)
CN (2) CN114949187A (es)
AU (1) AU2015294125B2 (es)
BR (1) BR112017001420A2 (es)
CA (1) CA2955704A1 (es)
CL (1) CL2017000191A1 (es)
CO (1) CO2017000571A2 (es)
DK (1) DK3171891T3 (es)
EA (1) EA039169B1 (es)
ES (1) ES3054696T3 (es)
FI (1) FI3171891T3 (es)
GB (1) GB201413240D0 (es)
HR (1) HRP20251560T1 (es)
IL (1) IL249981B (es)
LT (1) LT3171891T (es)
MX (1) MX2017001138A (es)
MY (1) MY196858A (es)
PL (1) PL3171891T3 (es)
PT (1) PT3171891T (es)
RS (1) RS67520B1 (es)
SG (1) SG11201700172WA (es)
SI (1) SI3171891T1 (es)
WO (1) WO2016012285A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) 2015-02-12 2015-04-01 Hansa Medical Ab Protein
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
UA130214C2 (uk) 2018-07-20 2025-12-24 Момента Фармасьютикалз, Інк. Фармацевтична композиція антитіл проти fcrn
IL288024B2 (en) 2019-05-14 2025-12-01 Provention Bio Inc Methods and compositions for preventing type
KR20220040476A (ko) * 2019-08-01 2022-03-30 메모리얼 슬로안 케터링 캔서 센터 개선된 면역치료법을 위한 세포 및 이의 용도
MX2022001380A (es) * 2019-08-01 2022-03-25 Momenta Pharmaceuticals Inc Anticuerpos de fcrn y metodos de uso de los mismos.
JP2023512014A (ja) 2020-01-28 2023-03-23 フリーライン セラピューティクス リミテッド ウイルスベクターに対する中和抗体力価を決定するための改善されたアッセイ
GB202002072D0 (en) * 2020-02-14 2020-04-01 Hansa Biopharma AB immunoglobulin detection and associated therapies
GB202003129D0 (en) * 2020-03-04 2020-04-15 Hansa Biopharma AB Conditioning regimen for transplant of stem cells
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods
GB202007431D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Cysteine protease
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
EP4215208A4 (en) * 2020-09-21 2024-11-20 Shanghai Bao Pharmaceuticals Co., Ltd. PHARMACEUTICAL COMBINATION AND USE THEREOF
US20230374542A1 (en) 2020-10-07 2023-11-23 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21)
JP2024515626A (ja) 2021-04-16 2024-04-10 アスクレピオス バイオファーマシューティカル， インコーポレイテッド 血液脳関門を横断し低減された液性応答を惹起する合理的ポリプロイドａａｖビリオン
EP4079848A1 (en) 2021-04-22 2022-10-26 Genovis Ab Immunoglobulin cleaving enzyme
AU2022283271A1 (en) 2021-05-24 2023-12-07 Provention Bio, Inc. Methods for treating type 1 diabetes
US20250325640A1 (en) 2021-11-15 2025-10-23 Hansa Biopharma AB Methods for enhancing adoptive cell transfer immunotherapies
JP2025509611A (ja) 2022-03-17 2025-04-11 アストラゼネカ アイルランド リミテッド 改善されたｉｇｇ－分解酵素及びその使用方法
JP2025538454A (ja) 2022-11-18 2025-11-28 サイズミック セラピューティク インコーポレイテッド Ｆｃ融合分子及びその使用
CN116087528A (zh) * 2022-12-27 2023-05-09 华中科技大学同济医学院附属同济医院 一种sqtsm1蛋白在卵巢早衰的应用
AU2024206486A1 (en) 2023-01-06 2025-08-14 Seismic Therapeutic, Inc. Protease variants and uses thereof
WO2025248469A1 (en) * 2024-05-28 2025-12-04 Biohaven Therapeutics Ltd. TREATMENT OF IgG-RELATED DISEASES
WO2025256977A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Novel igm and igg cleaving enzymes
WO2025256978A1 (en) 2024-06-13 2025-12-18 Bayer Aktiengesellschaft Variants of igm and igg cleaving enzymes

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JPH0612624B2 (ja) * 1984-06-20 1994-02-16 株式会社日立製作所 半導体集積回路装置
JP2000511888A (ja) * 1996-05-09 2000-09-12 ザ ジェネラル ホスピタル コーポレイション 混合キメリズム及び寛容
GB0511769D0 (en) * 2005-06-09 2005-07-20 Hansa Medical Ab Treatment
ATE548049T1 (de) 2005-06-09 2012-03-15 Hansa Medical Ab Verwendung von ides proteinase (von s. pyogenes) zur behandlung von autoimmunkrankheiten und transplantatabstossung
GB2427360A (en) * 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
GB0624874D0 (en) * 2006-12-13 2007-01-24 Hansa Medical Ab Treatment
PL2190984T3 (pl) * 2007-09-14 2014-02-28 Genovis Ab Sposoby i zestawy do oczyszczania i wykrywania glikozylowanego IgG
GB201115841D0 (en) * 2011-09-13 2011-10-26 Genovis Ab Protein and method
GB201201314D0 (en) * 2012-01-26 2012-03-07 Isis Innovation Composition
TWI626491B (zh) * 2012-12-10 2018-06-11 布萊恩荷登視覺協會 用於視力校正之具有一或多個多正焦區域之眼用光學透鏡
GB201413240D0 (en) * 2014-07-25 2014-09-10 Hansa Medical Ab Method
GB201502306D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB201502305D0 (en) * 2015-02-12 2015-04-01 Hansa Medical Ab Protein
GB202007434D0 (en) * 2020-05-19 2020-07-01 Hansa Biopharma AB Methods

Also Published As

Publication number Publication date
CN114949187A (zh) 2022-08-30
DK3171891T3 (da) 2025-12-15
GB201413240D0 (en) 2014-09-10
EA201790192A1 (ru) 2017-09-29
KR20230119267A (ko) 2023-08-16
MX2017001138A (es) 2017-06-07
US10973889B2 (en) 2021-04-13
KR102565244B1 (ko) 2023-08-10
US20170209550A1 (en) 2017-07-27
LT3171891T (lt) 2025-12-29
US20210260173A1 (en) 2021-08-26
EP3171891B1 (en) 2025-09-10
SI3171891T1 (sl) 2026-01-30
AU2015294125B2 (en) 2020-10-15
CA2955704A1 (en) 2016-01-28
IL249981A0 (en) 2017-03-30
EA039169B1 (ru) 2021-12-13
CN106714834A (zh) 2017-05-24
CO2017000571A2 (es) 2017-06-20
SG11201700172WA (en) 2017-02-27
PT3171891T (pt) 2025-11-25
ES3054696T3 (en) 2026-02-05
HRP20251560T1 (hr) 2026-01-16
JP2017522384A (ja) 2017-08-10
WO2016012285A3 (en) 2016-04-14
HK1232122A1 (en) 2018-01-05
JP6708641B2 (ja) 2020-06-10
EP4663755A2 (en) 2025-12-17
FI3171891T3 (fi) 2025-12-08
NZ728265A (en) 2024-03-22
MY196858A (en) 2023-05-05
IL249981B (en) 2022-08-01
RS67520B1 (sr) 2025-12-31
WO2016012285A2 (en) 2016-01-28
US20260000739A1 (en) 2026-01-01
AU2015294125A1 (en) 2017-02-02
US12397044B2 (en) 2025-08-26
KR20170039243A (ko) 2017-04-10
PL3171891T3 (pl) 2026-02-23
EP3171891A2 (en) 2017-05-31
BR112017001420A2 (pt) 2017-11-28

Similar Documents

Publication Publication Date Title
CL2017000191A1 (es) Método
SA519402159B1 (ar) بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
EA201891983A8 (ru) Комбинированная терапия антителами к cd73
EP4233873A3 (en) Implantable scaffolds for treatment of sinusitis
PH12018500714A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
MX2024000348A (es) Mavacamten para su uso en el tratamiento de la cardiomiopatia hipertrofica.
MX2020001270A (es) Anticuerpos anti-cd39, composiciones que comprenden anticuerpos anti-cd39, y metodos de uso de anticuerpos anti-cd39.
MX2021008053A (es) Metodos para monitorear y terapias para usarse en tratar el cancer.
EA201692477A1 (ru) Композиции и способы применения для лечения метаболических расстройств
CL2017000080A1 (es) Métodos para tratar el cáncer con inhibidores de tigit y agentes contra el cáncer
CL2017000335A1 (es) Tratamientos conjuntos con anticuerpos anti cd40
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
AR102553A1 (es) Terapia de combinación con agonistas de unión ox40 e inhibidores de tigit
PH12019502025A1 (en) Anti-tigit antigen-binding proteins and methods of use thereof
CL2016002088A1 (es) Anticuerpos monoclonales biespecificos contra il-13/il-17; ácido nucleico; célula huésped; método de producción del anticuerpo; inmunoconjugados; formulación farmacéutica; y usos de los anticuerpos biespecíficios para el tratamiento del asma moderada a severa y/o asma eosinofílica.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
MX2020004411A (es) Anticuerpos anti-cd40 para usarse en el tratamiento del sindrome de sjogren.
AU2017310412A8 (en) Method of improving connective tissue attachment using anti-sclerostin antibodies
MX2020003563A (es) Anticuerpo anti-pacap.
EA201591513A1 (ru) Терапевтическое применение антител к vegfr1 (варианты)
EA201990978A1 (ru) Антитела против pd-1